Name | Relationship | Holdings Value | Past Year Net Change | Change % | Report Date |
---|---|---|---|---|---|
Royalty Pharma Investments 2019 ICAV | Director, 10%+ Owner | $32M | Jan 31, 2022 | ||
Jerald Korn | Chief Operating Officer | $448K | Aug 12, 2022 | ||
Matthew Ros | Executive Vice President, Chief Strategy & Business Officer | $232K | Aug 16, 2021 | ||
Andrew Allen | Director | $51.7K | Jun 11, 2021 | ||
Carl Goldfischer | Director | $23K | Aug 12, 2022 | ||
Kenneth Bate | Director | $23K | Aug 12, 2022 | ||
Victoria Richon | Director | $23K | Aug 12, 2022 | ||
Michael F. Giordano | Director | $23K | Aug 12, 2022 | ||
Roy A. Beveridge | Director | $23K | Aug 12, 2022 | ||
Kevin T. Conroy | Director | $23K | Aug 12, 2022 | ||
David Mott | Director | $23K | Aug 12, 2022 | ||
Pablo G. Legorreta | Director, 10%+ Owner | $23K | Aug 12, 2022 | ||
Carol Stuckley | Director | $23K | Aug 12, 2022 | ||
Jeffery Kutok | Chief Scientific Officer | Aug 12, 2022 | |||
Shefali Agarwal | Consultant and Named Executive Officer | Aug 12, 2022 | |||
Grant C. Bogle | President and CEO, Director | Aug 12, 2022 | |||
Joseph Beaulieu | Senior Vice President, Finance and Corporate Controller | Aug 12, 2022 |
Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
---|